« Previous
Next »
Titles
- FDA could take stronger enforcement action against tobacco retailers with histories of sales to youth and other violations1
- FDA oversight1
- FDA repeatedly adapted emergency use authorization policies to address the need for COVID-19 testing1
- FDA’s approach to overseeing online tobacco retailers needs improvement1
- FDA’s work with the tri-agency task force for emergency diagnostics helped labs implement COVID-19 tests1
- Failure to respond to an ANDA complete response letter within the regulatory timeframe1
- Failure to respond to an ANDA complete response letter within the regulatory timeframe: guidance for industry1
- Federal Employees Health Benefits Program: Additional monitoring mechanisms and fraud risk assessment needed to better ensure member eligibility : report to congressional requesters1
- Federal prisons: monitoring efforts to implement COVID-19 recommendations and examining first step act implementation : testimony before the Subcommittee on Crime, Terrorism, and Homeland Security, Committee on the Judiciary, House of Representatives1
- Federal research: NIH could take additional actions to manage risks involving foreign subrecipients : report to congressional requesters1
- For Medicaid-enrolled children diagnosed with lead toxicity in five states, documentation reviewed for diagnoses and treatment services raises concerns1
- Foreign supplier verification programs for importers of food for humans and animals: guidance for industry1
- Formal meetings between FDA and ANDA applicants of complex products under GDUFA: guidance for industry1
- Format and content of a REMS document: guidance for industry1
- Fostering medical device improvement: FDA activities and engagement with the voluntary improvement program : guidance for industry and Food and Drug Administration staff1
- Four states reviewed received increased Medicaid COVID-19 funding even though they terminated some enrollees’ coverage for unallowable or potentially unallowable reasons1